A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Ceritinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Aug 2017 Planned End Date changed from 7 Aug 2018 to 8 Aug 2018.
- 01 Aug 2017 Planned primary completion date changed from 7 Aug 2018 to 8 Aug 2018.
- 12 Dec 2016 Planned number of patients changed from 105 to 85.